MCTL CLINICAL TRIALS
CURRENTLY ENROLLING IN CHINA

China has emerged as the global leader in adoptive cell therapy clinical trials — including MCTL — driven by aligned regulatory pathways, large patient populations, and substantial biotech investment. For international patients seeking access to investigational cell therapy, China is now the primary destination.

“A decade ago, US and European centres dominated cancer cell therapy research. Today, China runs more cell therapy clinical trials than any other country — and the MCTL ecosystem is among the most active areas.”

• Streamlined Regulatory Pathway

  China's NMPA (National Medical Products Administration) has implemented expedited pathways for cell therapy trials, particularly for advanced cancers with unmet need. This regulatory environment has supported rapid trial initiation and enrolment growth.

• Patient Population and Investment

  Large patient populations enable rapid trial enrolment. Substantial Chinese biotech investment (national policy support, venture capital, government grants) has produced an active commercial cell therapy ecosystem. The combination creates conditions for trial expansion unmatched elsewhere.

Active or recently active MCTL trial categories at major Chinese centres. Specific trial details change frequently — CancerFax verifies current enrolment status case-by-case.

MCTL clinical trials are concentrated at China's tier-1 academic medical centres — which combine high patient volumes, cell therapy manufacturing capability, and established research infrastructure. Centre selection depends on cancer type, trial availability, and patient logistics.

• Beijing Programmes

  The Cancer Hospital of the Chinese Academy of Medical Sciences and the 307th Hospital of PLA run multiple MCTL programmes across solid tumour indications. Beijing centres are particularly active in lung, gastric, and hepatocellular carcinoma trials.

• Shanghai Programmes

  Fudan University Shanghai Cancer Center, Shanghai Jiao Tong University, and Tongji Hospital host MCTL trials with particular strength in breast cancer, hepatocellular, and gastric cancer indications.

• Guangzhou Programmes

  Sun Yat-sen University Cancer Center is among the largest cell therapy research institutions in southern China, with active MCTL programmes across lung, breast, oesophageal, and nasopharyngeal cancer indications.

• Other Major Centres

  Tianjin Medical University Cancer Institute, West China Hospital (Chengdu), Zhongshan Hospital, and Peking Union Medical College host additional MCTL programmes. Centre choice depends on specific trial availability and patient logistics.

While specific trials have specific criteria, MCTL trials share common eligibility themes. Understanding these helps patients assess potential candidacy before formal screening.

• Disease and Treatment Status

  Most trials require histologically confirmed cancer of the specified type, measurable disease per RECIST criteria, and progression on a defined number of prior lines (typically 1–3 lines for second-line, 2+ lines for later-line trials). Patients still benefiting from standard treatments are generally directed to continue those first.

• Performance Status and Organ Function

  ECOG performance status 0–1 is standard. Adequate organ function — cardiac (ejection fraction >50%), renal (creatinine clearance >60 mL/min), hepatic (LFTs within 2.5× normal), pulmonary (FEV1 >50%) — and adequate bone marrow reserve (ANC >1500, platelets >75,000) are typically required.

• Common Exclusion Criteria

  Active uncontrolled infection, severe cardiac disease, recent CNS disease without stable control, autoimmune disease requiring immunosuppression, active hepatitis B or C (in some protocols), HIV (in some protocols), pregnancy, or prior allogeneic stem cell transplant typically exclude patients.

• Tumour-Specific Requirements

  Some MCTL trials require confirmation of specific antigen expression in the patient's tumour (e.g., HER2 positivity, PD-L1 expression, specific tumour-associated antigen profile). This may require fresh biopsy or testing on archived material. Confirm specific requirements during the screening process.

The practical pathway from initial interest to trial enrolment for international patients.

1. 1

   Step 1: Initial Case Review with CancerFax

   Upload medical records — pathology, biomarkers, treatment history, imaging, performance status. CancerFax's clinical team reviews the case and identifies whether MCTL trial enrolment is appropriate and which specific trials match.

2. 2

   Step 2: Trial Matching and Centre Selection

   Match the case against active trial criteria at multiple Chinese centres. Shortlist 2–4 trials based on disease match, eligibility criteria, centre location, and logistics.

3. 3

   Step 3: Centre Pre-Screening

   CancerFax coordinates initial case discussion with the principal investigators or trial coordinators at shortlisted centres. They confirm preliminary eligibility before formal screening.

4. 4

   Step 4: Travel to Centre for Formal Screening

   Once preliminary eligibility is confirmed, patient travels to the trial centre for full screening — physical examination, laboratory tests, fresh biopsy if required, imaging confirmation, and informed consent for the specific protocol.

5. 5

   Step 5: Apheresis and Trial Enrolment

   If formal screening confirms eligibility, the patient undergoes apheresis and begins the trial protocol. Cells are manufactured over 2–3 weeks; patient may return home or stay locally during manufacturing.

6. 6

   Step 6: Treatment Delivery and Follow-Up

   Patient returns to the centre for lymphodepletion and cell infusion. Hospital stay typically 1–2 weeks for infusion and post-infusion monitoring. Long-term follow-up coordinated with home oncology team after discharge.

MCTL trial costs vary by sponsorship structure. Some trials are fully sponsor-funded; others require patient contribution. Understanding the cost structure prevents financial surprises.

• Sponsor-Funded Trials

  Some MCTL trials are fully sponsor-funded for the experimental treatment itself — including the cell manufacturing, lymphodepletion, and infusion. Patients typically still pay for routine care costs (imaging, laboratory, hospitalisation beyond protocol-required) and travel/accommodation.

• Patient-Contribution Trials

  Other trials require patient contribution toward manufacturing or treatment delivery costs. Costs typically range from $30,000–$80,000 USD for the full treatment package — substantially less than FDA-approved CAR-T pricing but still meaningful. CancerFax confirms specific cost structure before commitment.

Explore the MCTL therapy knowledge base.

Frequently Asked Questions

Common questions about MCTL clinical trials in China.